AI models like AlphaFold have solved the 50-year-old protein folding problem, enabling scientists to predict molecular structures in hours instead of years and accelerating drug discovery for diseases from COVID-19 to Alzheimer's to cancer.
Digital twins—virtual replicas of human organs built from medical imaging, genetic data, and AI simulations—are transforming drug development by predicting how patients will respond to treatments before clinical trials begin. Companies like Sanofi and Adsilico are already using these models to cut drug testing time by 20%, reduce costs by $100 million, and improve trial success rates. By 2034, the healthcare digital twin market will reach $77.4 billion. While challenges around data bias, priv...
Loading featured articles...